| Rudolf Fahrig
Prof. Dr.rer.nat.habil | CEO
Founder of RESprotect GmbH, Inventor of RP101 | Geneticist, responsible for business and science. Conception and design of in vivo-screening systems and clinical studies. |
| Klaus Kutz
Prof. Dr. med. | CMO
Clinical Studies | Physician, long-time experience as Head of Clinical Pharmacology in two internationally operating pharmaceutical companies. |
| Jörg-Christian Heinrich
Dr.rer.nat. | CSO
Cell and Molecular Biology | Biologist, preclinical development of the drugs of the second generation. Elucidation of the mode of action of RP101 and 2nd generation substances. |
| Torsten Fahrig
Dr.-Ing. | COO/CFO
Operation and Finances | Computer Scientist, responsible for finances, marketing and organisation. |
| Andreas Koch
Dr.-Ing. | Director
Chemistry and Pharmacy | Chemist, long-time experience in chemical syntheses. Preparation of drug master files, FDA and EMEA approvals. |